SecBot SecBot
Insider Cluster (4 insiders) ·Filed Aug 20, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed2mo ago
Insider cluster: 4 insiders, $0.2M total
Actionable Insight • Neutral

Insider sales are economically immaterial (0.04% of market cap) and clustered just after a positive earnings report, likely liquidity-driven as blackout windows reopen. The COO's $128K sale is the largest, but still dwarfed by $283.7M cash and the $178.2M PRV gain. No bearish signal here; the earnings-fueled bull case (Danon Phase 2 data, extended runway) remains intact. Monitor for any 10b5-1 plan adoption by insiders or follow-on sales exceeding 0.5% of market cap before adjusting stance.

DirectionNeutral
Confidencehigh
Horizonweeks

RP-A501

● Neutral Named in this insider cluster
Impact
Phase
Phase 2 (pivotal/registrational)
Time to market
If the pivotal Phase 2 trial succeeds, a BLA submission for accelerated approval could follow in 2028-2029, given the 12-month endpoint timeline with last patient dosed by mid-2027.
Next catalyst
None dated

What to watchWatch for updates on enrollment of the remaining 9 patients in the pivotal Phase 2 trial and any interim data presentations at medical conferences in 2027. The FDA alignment in September 2026 de-risked the regulatory path, but the stock near its 52-week low reflects lingering safety concerns and a long wait until topline data (likely 2028). KRESLADI commercial traction is a separate value driver that could support the stock in the interim.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.51
T+0 close · Aug 20, 2026 · via day close
Latest settled
−38.46%
T+60 · $2.16
Vs SPY
−35.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 21 $3.51entry
  2. T+1 · 3mo ago +0.57%α +0.86% · $3.53
  3. T+5 · 3mo ago +9.97%α +9.50% · $3.86
  4. T+20 · 8w ago −6.84%α −7.85% · $3.27
  5. T+60 · 20h ago −38.46%α −35.10% · $2.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Four Rocket Pharmaceuticals insiders, including CEO Gaurav Shah and COO Christopher Stevens, sold a total of $164K in open-market sales over the past week. This cluster comes just 10 days after Q2 earnings that showed a GAAP net income of $123.2M, driven by a $178.2M PRV sale, extended cash runway into Q2 2028, and positive Danon disease Phase 2 data. However, sales are modest relative to the $401M market cap (0.04%), and the post-earnings timing aligns with a typical blackout-window opening, reducing informational significance per academic literature on cluster sells.

Key Financial Metrics

Direction
selling
Total Value
$164.0K
Insiders
4

Key Facts

  • CEO Gaurav Shah sold 2,293 shares at $3.381 for ~$8K on 2026-08-18.
  • COO Christopher Stevens sold 36.7K shares at $3.50 for $128K on 2026-08-11.
  • Total insider sales of $164K represent ~0.04% of the $401M market cap, below the 0.1% materiality threshold.
  • Cluster occurred 10 days after a bullish Q2 earnings 8-K (GAAP net income $123.2M vs. $68.9M loss YoY, cash runway extended to Q2 2028).
  • All four sales are open-market (code S), no 10b5-1 plan data provided, but post-earnings timing is consistent with routine blackout-window opening.

Financial Impact

Total insider sales of $164K, 0.04% of market cap. Trivial relative to $401M valuation and $283.7M cash position.

insider ownershipfloat

Risk Factors

  • Insider sales cluster post-earnings may still unsettle retail holders given RCKT's 55% analyst bullish rating but $401M depressed market cap.
  • If COO Stevens continues selling larger blocks in subsequent weeks, the pattern could shift from routine to concerning.
  • No 10b5-1 plan disclosure, lack of formal trading plan increases uncertainty about intent.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RCKT-1787292248070

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 21, 2026